Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

UPS (UPS) Q4 2024 Earnings Call Transcript

View original at finance.yahoo.com
UPS (UPS) Q4 2024 Earnings Call Transcript Image source: The Motley Fool. Date Thursday, January 30, 2025 at 8:30 a.m. ET Call participants Chief Executive Officer — Carol B…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • UPS is not a company that's shrinking, it's a company that's growing

    80% confidence

  • Global GDP will grow 2.5% in 2025 compared to 2024

    80% confidence

  • UPS expects no material financial impact from SurePost insourcing

    80% confidence

  • UPS will expand domestic operating margin in every quarter of 2025

    80% confidence

  • The Amazon volume reduction was UPS's decision, not Amazon's request, to take control of UPS's destiny

    80% confidence

  • UPS is growing profit dollars, not just margin

    80% confidence

  • The small package market excluding Amazon will grow in low single digits in 2025

    80% confidence

  • Real exports and industrial production will grow 2% YoY in 2025

    80% confidence

  • UPS was concerned about service deterioration under new USPS operating model

    80% confidence

  • U.S. manufacturing is expected to be positive in Q1 2025 after 7 negative quarters

    80% confidence

  • UPS believes it is ahead of competitors in generative AI deployment

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com